A Hearn

Emory Healthcare — United States

Medicine · Health Sciences

16h-index976citations51works7.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asthma and respiratory diseases(27), Eosinophilic Esophagitis(12), Respiratory and Cough-Related Research(8), Pediatric health and respiratory diseases(7), COVID-19 Clinical Research Studies(6)

Publications46 total

Late Breaking Abstract - Severe asthma biologic switches: an overview of outcomes at a UK regional centre
2025
Disseminated Mycobacterium Avium Complex Masquerading as a Lymphoproliferative Disorder: A Case Report
American Journal of Respiratory and Critical Care Medicine·2025
OCCULT MALIGNANCY OF UNKNOWN ORIGIN PRESENTING AS LYMPHANGITIC CARCINOMATOSIS
CHEST Journal·2024
DISSEMINATED CRYPTOCOCCUS NEOFORMANS IN A PATIENT WITH RHEUMATOID ARTHRITIS ON METHOTREXATE MONOTHERAPY
CHEST Journal·2024· 1 citedOpen Access
Preserved antibody responses to COVID-19 vaccination and lower odds of developing COVID-19 in adults with severe asthma
The Journal of Allergy and Clinical Immunology In Practice·2024· 3 citedOpen Access
Long-Term Effectiveness of Anti-IL-4R Therapy Following Suboptimal Response to Anti-IL-5/5R Therapy in Severe Eosinophilic Asthma
The Journal of Allergy and Clinical Immunology In Practice·2024· 25 cited
IGF2BP3 modulates type 2 immunity in severe asthma: A novel regulator of IL-4/IL-13 signalling
2024
Refractory prinzmetal variant angina successfully managed with prazosin: a case report
The American Journal of the Medical Sciences·2024Open Access
Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis
The Journal of Allergy and Clinical Immunology In Practice·2024· 26 cited
S63 Long-term effectiveness of anti-IL4R therapy following suboptimal response to anti-IL5/5R therapy in severe eosinophilic asthma
2023Open Access
P171 Evaluation of a biomarker-led rapid access review clinic to support steroid stewardship in patients with asthma
2023Open Access
M20 Preserved antibody responses to COVID-vaccines and lower odds of developing COVID in people with severe asthma
2023Open Access
M22 Change in FeNO with dupilumab and tezepelumab in severe eosinophilic asthma
2023Open Access
The impact of steroid-sparing biologic therapies on weight loss in obese individuals with severe eosinophilic asthma
European Respiratory Journal·2023· 11 cited
Alveolar macrophages from people with severe eosinophilic asthma show differential antiviral responses to human rhinovirus 16 and SARS-CoV-2
03.02 - Airway cell biology and immunopathology·2022
COVID‐19 in the absence of eosinophils: The outcome of confirmed SARS‐CoV‐2 infection whilst on treatment with benralizumab
Allergy·2022· 9 citedOpen Access
Effectiveness of Anti-IL4R Therapy Following Suboptimal Response to Anti-IL5/5R Therapy in Severe Eosinophilic Asthma
2022
Alveolar macrophages from people with severe eosinophilic asthma show differential antiviral responses to human rhinovirus 16 and SARS-CoV-2.
2022
The prevalence of mucus plugging in severe eosinophilic asthma and its relationship to clinical efficacy of anti–IL-5R treatment
The Journal of Allergy and Clinical Immunology In Practice·2022· 10 cited
A pragmatic guide to choosing biologic therapies in severe asthma
Breathe·2021· 48 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Jaideep Dhariwal(24), Cris Roxas(24), G d’Ancona(22), David J. Jackson(21), Mariana Fernandes(16), Linda K. Green(13), Brian D. Kent(13), Joanne Kavanagh(12), Louise Thomson(12), Alexandra M. Nanzer(12), AM Nanzer(9), L Thomson(8), J Lam(6), J Kavanagh(6), Jessica Gates(5), DJ Jackson(5), Alexandra M. Nanzer(4), Victoria Payne(4), BD Kent(4), DJ Jackson(4)